Harbour BioMed and Sinopharm have formed a strategic Innovation Consortium to co-develop biologics in oncology and immune-mediated inflammatory disease.
Harbour BioMed, a global biopharmaceutical company with operations in Cambridge, Mass.; Rotterdam, Netherlands; and Shanghai, China, has entered a
"We are delighted to establish this strategic partnership with Sinopharm," said
The 2 companies will work across the full R&D lifecycle for innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases, and other therapeutic areas. Harbour BioMed will apply its Harbour Mice fully human antibody technology platform and artificial intelligence (AI)-enabled drug discovery capabilities to the discovery and optimization of antibody candidates alongside Sinopharm.
Sinopharm will contribute
Dr Wang noted that Harbour BioMed has already established strategic collaborations with global pharmaceutical companies including AstraZeneca,2 Bristol Myers Squibb,3 and Pfizer,4 and described the Sinopharm partnership as an extension of the company's platform-driven approach in China.1
Commenting in the release, Sinopharm characterized the consortium as a move to optimize resource allocation and enhance R&D efficiency, framing the deal as part of a broader strategy that synergizes independent innovation with open collaboration.1 The company said it hopes the partnership will help bring more high-quality, affordable treatment options to patients.1
Harbour Mice is Harbour BioMed's proprietary antibody technology platform, generating fully human monoclonal antibodies in both the conventional two-heavy, two-light chain (H2L2) format and the heavy chain-only (HCAb) format. Built on the HCAb format, the company's HBICE bispecific antibody technology is designed to enable tumor-killing effects that traditional combination therapies cannot achieve, while its HCAb Plus technology is intended to provide comprehensive modality solutions for developing multispecific medicines across different disease areas.
The company has also launched a fully human generative AI HCAb model, powered by its Hu-mAtrIx AI platform, which the company said is intended to accelerate development of new antibody therapies.1 The company describes its combination of Harbour Mice, HBICE, HCAb Plus, a single B-cell cloning platform, and AI technologies as a distinctive antibody discovery engine for next-generation therapeutic antibodies.1
Harbour BioMed is focused on discovering and developing novel antibody therapeutics in immunology, oncology, and other disease areas, building its pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Sinopharm is described in the release as the national team in China's pharmaceutical and healthcare sector, participating in the full industry chain from research and manufacturing to distribution.1 Its scientific and technological innovation remains central to its development strategy.
Terms of the collaboration, including deal value, milestone structure, and consortium governance, were not disclosed in the announcement.1
